530 related articles for article (PubMed ID: 29409610)
1. There and back again: An immunotherapy tale.
Guo Y; Krupnick AS
J Thorac Cardiovasc Surg; 2018 Apr; 155(4):1771-1774. PubMed ID: 29409610
[No Abstract] [Full Text] [Related]
2. KEYNOTE-024: Unlocking a pathway to lung cancer cure?
Rusch VW; Chaft J; Hellmann M
J Thorac Cardiovasc Surg; 2018 Apr; 155(4):1777-1780. PubMed ID: 29395215
[No Abstract] [Full Text] [Related]
3. Clinical benefit to programmed death-1 inhibition for non-small-cell lung cancer is associated with higher blood eosinophil levels.
Sibille A; Henket M; Corhay JL; Louis R; Duysinx B
Acta Oncol; 2020 Mar; 59(3):257-259. PubMed ID: 31755328
[No Abstract] [Full Text] [Related]
4. [Immuno-checkpoint inhibitor resistance and strategy in lung cancer].
Jiang WR; Fang LP; Chang N; Zhang J
Zhonghua Jie He He Hu Xi Za Zhi; 2020 Jul; 43(7):603-606. PubMed ID: 32629564
[TBL] [Abstract][Full Text] [Related]
5. Baseline corticosteroids reduce activity of PD-L1 blockade.
Gourd E
Lancet Oncol; 2018 Oct; 19(10):e515. PubMed ID: 30177497
[No Abstract] [Full Text] [Related]
6. Clinical Outcomes in Patients With Metastatic Lung Cancer Treated With PD-1/PD-L1 Inhibitors and Thoracic Radiotherapy.
Hwang WL; Niemierko A; Hwang KL; Hubbeling H; Schapira E; Gainor JF; Keane FK
JAMA Oncol; 2018 Feb; 4(2):253-255. PubMed ID: 28973343
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapeutic approaches for small-cell lung cancer.
Iams WT; Porter J; Horn L
Nat Rev Clin Oncol; 2020 May; 17(5):300-312. PubMed ID: 32055013
[TBL] [Abstract][Full Text] [Related]
8. Is immune checkpoint inhibition part of standard therapy for stage III non-small cell lung cancer?
Patel JD; Chmura SJ
Cancer; 2018 Jul; 124(14):2878-2880. PubMed ID: 29906817
[No Abstract] [Full Text] [Related]
9. Current status of immune checkpoint inhibitors in treatment of non-small cell lung cancer.
Lim SW; Ahn MJ
Korean J Intern Med; 2019 Jan; 34(1):50-59. PubMed ID: 30612418
[TBL] [Abstract][Full Text] [Related]
10. Finally, after decades, immune checkpoint inhibitors dethroned the standard of care of small-cell lung cancer.
Saleh K; Khalife-Saleh N; Kourie HR
Immunotherapy; 2019 Apr; 11(6):457-460. PubMed ID: 30860440
[No Abstract] [Full Text] [Related]
11. Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic.
Vilariño N; Bruna J; Bosch-Barrera J; Valiente M; Nadal E
Cancer Treat Rev; 2020 Sep; 89():102067. PubMed ID: 32682248
[TBL] [Abstract][Full Text] [Related]
12. The progress and confusion of anti-PD1/PD-L1 immunotherapy for patients with advanced non-small cell lung cancer.
Zhang S; Bai X; Shan F
Int Immunopharmacol; 2020 Mar; 80():106247. PubMed ID: 32007710
[TBL] [Abstract][Full Text] [Related]
13. Role of immune-checkpoint inhibitors in lung cancer.
Jain P; Jain C; Velcheti V
Ther Adv Respir Dis; 2018; 12():1753465817750075. PubMed ID: 29385894
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy in Advanced Non-Small Cell Lung Cancer.
Huang J; Reckamp KL
Semin Respir Crit Care Med; 2020 Jun; 41(3):400-408. PubMed ID: 32450594
[TBL] [Abstract][Full Text] [Related]
15. Clinical features affecting survival in metastatic NSCLC treated with immunotherapy: A critical review of published data.
Passaro A; Attili I; Morganti S; Del Signore E; Gianoncelli L; Spitaleri G; Stati V; Catania C; Curigliano G; de Marinis F
Cancer Treat Rev; 2020 Sep; 89():102085. PubMed ID: 32771858
[TBL] [Abstract][Full Text] [Related]
16. Use of Immunotherapy in Extensive-Stage Small Cell Lung Cancer.
Konala VM; Madhira BR; Ashraf S; Graziano S
Oncology; 2020; 98(11):749-754. PubMed ID: 32663833
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of PD-1/PD-L1 inhibitors in patients with advanced non-small cell lung cancer: A meta-analysis of randomized clinical trials.
Peng TR; Wu TW
Thorac Cancer; 2019 May; 10(5):1176-1181. PubMed ID: 30969033
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of immune checkpoint blockade for brain metastases.
Harary M; Reardon DA; Iorgulescu JB
CNS Oncol; 2019 Jun; 8(2):CNS33. PubMed ID: 30854898
[No Abstract] [Full Text] [Related]
19. First-Line Treatment of Non-Small-Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors.
Bylicki O; Barazzutti H; Paleiron N; Margery J; Assié JB; Chouaïd C
BioDrugs; 2019 Apr; 33(2):159-171. PubMed ID: 30825132
[TBL] [Abstract][Full Text] [Related]
20. Toxicity management with combination chemotherapy and programmed death 1/programmed death ligand 1 inhibitor therapy in advanced lung cancer.
Hoffner B; Leighl NB; Davies M
Cancer Treat Rev; 2020 Apr; 85():101979. PubMed ID: 32078962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
